Market research
KA6N.F Karo Pharma AB (publ)
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- 10.23
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.09
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 2B
- P/E ratio
- 10.23
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.09
About
About Karo Pharma AB (publ)
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands. It sells its products in approximately 90 countries with Europe and the Nordic region markets through direct sales organizations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is headquartered in Stockholm, Sweden.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the KA6N.F discussion.
5 years, 5 months ago
Karo Pharma AB (publ) is currently in a long term uptrend where the price is trading 4.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.0.
Karo Pharma AB (publ)'s total revenue rose by 11.1% to $721M since the same quarter in the previous year.
Its net income has dropped by 17.6% to $-27M since the same quarter in the previous year.
Finally, its free cash flow grew by 263.9% to $73M since the same quarter in the previous year.
Based on the above factors, Karo Pharma AB (publ) gets an overall score of 4/5.